Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency – CYNDERELA-HF Study
Condition(s):Cardiorenal SyndromeLast Updated:March 21, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Cardiorenal SyndromeLast Updated:March 21, 2018Terminated
Condition(s):Empagliflozin in Cardiorenal Syndrome Type 1Last Updated:February 7, 2024Not yet recruiting
Condition(s):Cardio-renal SyndromeLast Updated:October 9, 2018Unknown status
Condition(s):Cardiorenal SyndromeLast Updated:September 14, 2020Completed
Condition(s):Cardiorenal SyndromeLast Updated:August 10, 2018Withdrawn
Condition(s):Cardiorenal SyndromeLast Updated:January 24, 2024Not yet recruiting
Condition(s):Cardio-Renal SyndromeLast Updated:June 28, 2019Withdrawn
Condition(s):Cardiorenal Syndrome Type 1Last Updated:October 5, 2023Recruiting
Condition(s):Cardio-Renal SyndromeLast Updated:January 22, 2015Unknown status
Condition(s):Cardiorenal Syndrome; Acute Kidney Injury; Decompensated Heart Failure; Fluid Overload; Ultrasound Therapy; ComplicationsLast Updated:July 10, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.